AzTrials
AzTrials

StrokeMAESTRONCT07860333

Mobilisation After Endovascular Stroke Treatment

An observational study of Stroke and Acute Ischemic Stroke, run by Karolinska Institutet at 2 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to learn how the timing of mobilisation after endovascular thrombectomy (EVT) affects complications in patients with acute ischaemic stroke. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Mobilisation
How many people
400 participants
Where
2 sitesin 2 countries
Study dates
7 May 2026to 31 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients with acute ischaemic stroke treated with endovascular thrombectomy.

Who may be able to join

  • Undergone endovascular thrombectomy for acute ischaemic stroke
  • Minimum 18 years old

Who cannot join

  • Residing from outside primary catchment area
  • Spending more than 24 hrs in ICU post thrombectomy

Trial locations and contacts

2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Karin Crantz, PhD-student contact

+46706617369

karin.crantz@ki.se

Eric Thelin, Associate professor contact

+46 73-9365450

eric.thelin@ki.se

2 sites in 2 countries

Finland1 site, 1 recruiting
  • TAYS Tampere University Hospital

    Tampere

    Tomi Sarkanen, +358 3 31166664, tomi.sarkanen@pirha.fi

    Recruiting

Other trials in Finland

Sweden1 site, 1 recruiting
  • Karolinska Institutet

    Stockholm

    Karin Crantz, +46 70-6617369, karin.crantz@ki.se

    Recruiting

Other trials in Sweden

About this study

Official title: Mobilisation After Endovascular Stroke Treatment - A Prospective Multicentre Cohort Study

The goal of this observational study is to learn how the timing of mobilisation after endovascular thrombectomy (EVT) affects complications in patients with acute ischaemic stroke. The main questions it aims to answer are:

Does mobilisation approximately 12 hours after EVT, compared to approximately 24 hours after EVT, affect the risk of complications such as access site haematoma (ASH), venous thromboembolism (VTE), infections, and delirium? How common are these complications after EVT, and which factors are associated with increased risk?

Participants undergoing EVT as part of their regular stroke care at two hospitals with different mobilisation routines will be followed during their hospital stay. Researchers will collect information about mobilisation timing, complications, clinical assessments, and medical history using case report forms, electronic health records, and national stroke registries.

Read the detailed description

Title Mobilisation After Endovascular STROke treatment (MAESTRO): A prospective multicentre cohort study

Background and Rationale Stroke remains one of the leading causes of death and long-term disability worldwide. Each year, approximately 12-15 million people experience a stroke, with ischaemic stroke accounting for around two-thirds of cases. In Sweden alone, more than 26,000 individuals are affected annually, and the majority of patients are elderly. Beyond mortality, stroke often results in significant disability and dependency, requiring extensive rehabilitation and long-term care.

Over the past decade, endovascular thrombectomy (EVT) has revolutionised treatment for acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO). Randomised controlled trials have demonstrated substantial improvements in functional outcome for patients undergoing EVT compared to medical therapy alone, with benefits extending up to 24 hours after stroke onset. EVT has therefore become standard of care for selected patients with LVO.

While EVT has improved prognosis, it also introduces new challenges in the acute post-procedural phase. Most procedures are performed via femoral artery access, necessitating a period of strict bed rest to reduce the risk of access site haematoma (ASH). Patients often recover neurologically within hours, however, and may wish to mobilise earlier than current routines allow. The optimal timing of mobilisation after EVT remains unclear. Early mobilisation may reduce complications of immobility, but may also increase the risk of ASH. Conversely, prolonged bed rest may lower the risk of ASH but increases the risk of venous thromboembolism (VTE), infections such as pneumonia and urinary tract infection (UTI), and delirium. These complications are common after stroke, associated with worse outcomes, and prolong hospital stay.

Reported incidence of ASH varies widely, from 1% to 10%, likely due to inconsistent definitions and underreporting.

VTE after EVT has been reported in more than a quarter of patients in some studies, particularly among those with severe motor deficits or prolonged procedures. Post-stroke pneumonia affects more than one third of thrombectomy-treated patients and is independently associated with increased mortality and reduced independence. Delirium is a frequent complication among acute stroke patients, characterised by altered consciousness, disorganised thinking or disorientation, psychomotor disturbances, and circadian rhythm disruption, and is associated with worse outcomes. However, evidence regarding delirium after mechanical thrombectomy (MT) remains limited, as most previous studies were conducted in mixed stroke cohorts with few MT cases or predate the thrombectomy era. Together, these complications underscore the clinical importance of identifying safe and effective mobilisation strategies.

Despite the relevance of these issues, few studies have systematically investigated mobilisation after EVT. Available evidence is limited, definitions vary across studies, and results are contradictory. There is currently no consensus on when mobilisation should be initiated after EVT, leaving clinicians with considerable uncertainty. This knowledge gap has direct implications for patient safety, recovery, and the development of evidence-based care protocols.

Aim and Research Questions The overarching aim of this study is to investigate how the timing of mobilisation after EVT influences the occurrence of complications. The study will also describe the frequency, timing, and risk factors of complications related to mobilisation and immobilisation.

Research questions:

  1. What is the frequency of ASH, VTE, delirium, and infections after EVT, and which factors are associated with increased risk?
  2. How does timing of first mobilisation (12 vs 24 hours) affect the incidence of these complications?
  3. When do these complications occur in relation to EVT completion and first mobilisation? Methods Study design This is a prospective multicentre cohort study conducted at two hospitals with different mobilisation routines after EVT: a Swedish centre where patients are mobilised at approximately 12 hours post-procedure, and a Finnish centre where mobilisation occurs after approximately 24 hours. The design allows for systematic comparison of the two care protocols.

Participants and eligibility All adult patients (≥ 18 years) undergoing endovascular thrombectomy (EVT) for acute ischaemic stroke (AIS) at either participating centre will be consecutively screened for eligibility according to the inclusion and exclusion criteria listed below.

Inclusion criteria

  • Adult patient (≥ 18 years)
  • Undergoing EVT for acute ischaemic stroke Exclusion criteria
  • Patient residing outside the hospital's primary catchment area (due to difficulties following data when patient is transferred to primary hospital)
  • Inability of both patient and next of kin to understand the study information, making informed consent impossible (applicable to Finland)
  • Patients who remain in the intensive care unit (ICU) for more than a few hours post-procedure, as key early post-EVT events (e.g., mobilisation timing, access-site observation, and early complications) would not be captured due to lack of CRF registration in ICU settings
  • For outcome-specific analyses: patients with pre-existing venous thromboembolism (VTE), delirium, or infection at the time of inclusion will be excluded from the corresponding outcome analyses Recruitment and inclusion will be performed consecutively by dedicated and trained staff at each centre according to a standardised protocol (see Appendix 2, Participant Inclusion Form. Informed consent will be obtained from the patient or, when necessary, from a legally authorised representative or next of kin (see Appendix 3, Informed Consent Form).

In Sweden, presumed consent will be applied in rare cases where neither the patient nor a next of kin can provide consent, for example due to severe aphasia or unconsciousness. In such cases, inclusion will occur since participation poses no additional burden or risk, and only when every reasonable effort will have been made to obtain informed consent as soon as possible. No patient who expresses unwillingness or hesitation will ever be included.

Exposure and outcomes The primary exposure is the timing of first mobilisation after EVT, defined by local routine and recorded prospectively for each patient. Mobilisation includes sitting at the bedside with feet on the floor or in a chair/wheelchair, standing, or walking. Positioning in bed with elevated head of bed does not count as mobilization in this study. The primary outcome is ASH. Secondary outcomes include VTE (deep vein thrombosis or pulmonary embolism), infections (pneumonia or urinary tract infection), and delirium. The timing of these events in relation to EVT completion and mobilisation will be documented when available.

Data collection

Data collection is based on three complementary components:

  1. prospective case report forms (CRF) completed by clinical staff during hospitalisation,
  2. retrospective extraction from electronic health records (EHR)
  3. registry data from Riksstroke and EVAS (only applicable to Sweden). All data will be retrospectively transferred into REDCap.

The prospective CRF (see Appendix 1, CRF Prospective monitoring) includes:

  • Timing, type, duration, and initiator of first mobilisation and whether mobilisation was interrupted due to clinical deterioration (single entry)
  • Time of occurrence of ASH, including grading of haematoma severity (grade 1-3), the patient's mobility level at the time of onset (lying still in bed, moving in bed, sitting, standing, or walking), and whether the haematoma was detected at onset or later during subsequent care (single entry)
  • Three daily limb inspections for signs of DVT, supplemented by Wells Score when indicated. Any use of compression devices is also recorded.
  • Delirium screening three times daily using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).

Prospective data will be registered for as long as the patient remains admitted to the stroke unit, but for a maximum of five days, after which registration will stop.

Retrospective variables are obtained primarily from EHR, supplemented by national quality registries when not available in EHR (applicable for Sweden). These include demographics, comorbidities, medications, stroke severity, radiological findings, EVT-procedural details, blood pressure variability, infections (laboratory markers, antibiotic use, discharge diagnoses), VTE (discharge diagnoses or imaging reports), length of stay, discharge destination, functional status (Modified Rankin Scale [mRS] at 3 months), and mortality.

In Finland, due to national legislation requiring informed consent prior to data collection, early clinical data may in rare cases be retrieved retrospectively after inclusion and consent. This is possible as relevant parameters are already routinely documented within the local stroke care programme. It should be emphasised, however, that the study is primarily prospective, and any retrospective retrieval will only serve to capture early indicators of complications occurring before consent could be obtained.

Sample size and analysis A preliminary sample size calculation, assuming an ASH incidence of 10% in Finland and 20% in Sweden, indicated that approximately 400 patients (200 per site) are required to detect a statistically significant difference with α = 0.05 and power = 80%. This estimate is based on available literature and current clinical practice. Descriptive statistics will be used to summarise baseline characteristics and outcome frequencies. Categorical variables will be presented as counts and percentages, and continuous variables as means with standard deviations or medians with interquartile ranges.

Associations between mobilisation timing and complications will be analysed using multivariable logistic regression models, adjusting for potential confounders such as age, stroke severity, comorbidities, and procedural factors. Time-to-event analyses (Cox regression) may be applied where exact timing data are available. Subgroup analyses may be performed depending on data quality and sample size. Missing data will be handled using appropriate statistical methods depending on the extent and pattern of missingness.

Ethical considerations This study is observational and does not alter clinical care. Patients receive treatment according to the standard routines of each hospital. Prospective assessments, such as delirium screening, limb inspection, and ASH grading, are non-invasive, take only a few minutes, and entail no additional risk or discomfort for the patient. Data will be pseudonymised and stored in REDCap on secure EU servers, with access restricted to authorised research staff. All handling of personal data will comply with the General Data Protection Regulation (GDPR) and Karolinska Institutet's information security policies.

Significance This study addresses a critical knowledge gap in post-thrombectomy stroke care. By systematically comparing two mobilisation routines and documenting the frequency, timing, and risk factors of major complications, the study will generate evidence to guide safer and more individualised mobilisation protocols after EVT. The results may contribute to reducing complication rates, improving functional outcomes, and informing future clinical guidelines. Furthermore, the findings will provide a valuable basis for future scientific publications and for advancing the evidence base in stroke nursing and post-EVT care.

Being tested
Mobilisation
Keywords
acute ischaemic stroke, endovascular thrombectomy, early mobilisation, complications, access site haematoma, delirium, venous thromboembolism, infections, stroke nursing, observational study, prospective multicentre cohort study
Medical subject headings
Stroke, Ischemic Stroke, Delirium, Venous Thromboembolism, Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MobilisationOther

    Out of bed mobilisation, such as sitting on the edge of the bed, standing or walking with or without support.

Study groups in NCT07860333
Study groupRoleWhat they receive
Later mobilisationFinnish cohort, mobilised after 24 hrs
Receives: Other: Mobilisation
Earlier mobilisationSwedish cohort, mobilised after 12 hrs
Receives: Other: Mobilisation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Access site haematoma

    Bleeding from puncture site

    Measured: From completion of endovascular thrombectomy (baseline) to discharge from the stroke unit, up to 5 days.

Secondary outcomes (4)
  1. sICH

    Symptomatic intracranial haemorrhage

    Measured: Within 36 hours after completion of endovascular thrombectomy

  2. Venous thromboembolism

    Blood clots in venous system, such as deep vein thrombosis and/or pulmonary embolism.

    Measured: From completion of endovascular thrombectomy until discharge from the acute care hospital, assessed up to approximately 30 days.

  3. Infections

    Urinary tract infections, pneumonia and/or sepsis.

    Measured: From completion of endovascular thrombectomy until discharge from the acute care hospital, assessed up to approximately 30 days.

  4. Delirium

    Acute confusion, identified with Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)

    Measured: From completion of endovascular thrombectomy (Baseline) to discharge from the stroke unit, up to 5 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Oct 2026
  2. Study start7 May 2026
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07860333
Sponsor's protocol ID
4-1283/2026
Acronym
MAESTRO
Status last verified
Oct 2026
First submitted
7 Jul 2026
Last updated
6 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke and Acute Ischemic Stroke, run by Karolinska Institutet at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Finland, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Karin Crantz, PhD-student (+46706617369, karin.crantz@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Access site haematoma (time frame: From completion of endovascular thrombectomy (baseline) to discharge from the stroke unit, up to 5 days.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Mobilisation After Endovascular Stroke Treatment | AzTrials